{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:02:33Z","timestamp":1789614153716,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031283","name":"Sanofi France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031283","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP#180712"],"award-info":[{"award-number":["RP#180712"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-158"],"award-info":[{"award-number":["BCRF-158"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020908","name":"Pfizer France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020908","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.breast.2026.104894","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:42:26Z","timestamp":1786117346000},"page":"104894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-5492","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9rique","family":"Penault-Llorca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9691-5536","authenticated-orcid":false,"given":"Amelie","family":"Lusque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0724-0659","authenticated-orcid":false,"given":"Thomas","family":"Filleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0448-196X","authenticated-orcid":false,"given":"Lili","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Baehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Dalenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Lacroix-Triki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6291-9533","authenticated-orcid":false,"given":"Pascal","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8821-2168","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1526-184X","authenticated-orcid":false,"given":"W. Fraser","family":"Symmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.breast.2026.104894_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-Gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.breast.2026.104894_bib2","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"10384","key":"10.1016\/j.breast.2026.104894_bib3","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Electronic address bocoau, early breast cancer trialists' collaborative G. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials","volume":"401","year":"2023","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.breast.2026.104894_bib4","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104894_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104894_bib6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10549-013-2416-2","article-title":"PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer","volume":"138","author":"Martin","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.breast.2026.104894_bib7","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3642","article-title":"Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+\/HER2- breast cancer patients: results from the GEICAM 9906 trial","volume":"16","author":"Martin","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2026.104894_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/npjbcancer.2015.23","article-title":"PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)","volume":"2","author":"Liu","year":"2016","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104894_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10549-017-4550-8","article-title":"21-Gene recurrence score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28\/NRG oncology","volume":"168","author":"Mamounas","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2026.104894_bib10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12885-018-4331-8","article-title":"The 21-gene recurrence Score(R) assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)","volume":"18","author":"Penault-Llorca","year":"2018","journal-title":"BMC Cancer"},{"issue":"16","key":"10.1016\/j.breast.2026.104894_bib11","first-page":"1","article-title":"SET-ER\/PR - a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer","volume":"5","author":"Sinn","year":"2019","journal-title":"NPJ Breast Cancer"},{"issue":"27","key":"10.1016\/j.breast.2026.104894_bib12","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1200\/JCO.2010.28.4273","article-title":"Genomic index of sensitivity to endocrine therapy for breast cancer","volume":"28","author":"Symmans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104894_bib13","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/clinchem\/hvaa105","article-title":"Technical validity of a customized assay of sensitivity to endocrine therapy using sections from fixed breast cancer tissue","volume":"66","author":"Lau","year":"2020","journal-title":"Clin Chem"},{"issue":"9","key":"10.1016\/j.breast.2026.104894_bib14","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/clinchem\/hvab068","article-title":"Intra- and interlaboratory reproducibility of the sensitivity to endocrine therapy assay for stage II\/III breast cancer","volume":"67","author":"Bossuyt","year":"2021","journal-title":"Clin Chem"},{"issue":"10","key":"10.1016\/j.breast.2026.104894_bib15","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO-24-01875","article-title":"Adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer","volume":"43","author":"Metzger Filho","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104894_bib16","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-26-0177","article-title":"Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM\/9906 trial","author":"Martin","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.breast.2026.104894_bib17","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1200\/JCO.22.01499","article-title":"Evaluation of the sensitivity to endocrine therapy index and 21-Gene breast recurrence score in the SWOG S8814 trial","volume":"41","author":"Speers","year":"2023","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.breast.2026.104894_bib18","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","article-title":"Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial","volume":"24","author":"Roche","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104894_bib19","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1634\/theoncologist.2011-0442","article-title":"Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial","volume":"17","author":"Coudert","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2026.104894_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116152","article-title":"Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score(R) in node-positive breast cancer: independent validation in the PACS-01 trial","volume":"233","author":"Penault-Llorca","year":"2026","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.breast.2026.104894_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001216","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration","volume":"9","author":"Altman","year":"2012","journal-title":"PLoS Med"},{"issue":"21","key":"10.1016\/j.breast.2026.104894_bib22","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/jnci\/djp335","article-title":"Use of archived specimens in evaluation of prognostic and predictive biomarkers","volume":"101","author":"Simon","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"10.1016\/j.breast.2026.104894_bib23","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1200\/JCO.20.03613","article-title":"Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.breast.2026.104894_bib24","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update","volume":"40","author":"Andre","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104894_bib25","year":"2024","journal-title":"Breast Cancer"},{"issue":"12","key":"10.1016\/j.breast.2026.104894_bib26","first-page":"4610","article-title":"Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment","volume":"6","author":"Symmans","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.breast.2026.104894_bib27","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1073\/pnas.0408974102","article-title":"Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer","volume":"102","author":"Rouzier","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.breast.2026.104894_bib28","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.annonc.2021.02.011","article-title":"Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+\/HER2-) breast cancer before chemo-endocrine therapy","volume":"32","author":"Du","year":"2021","journal-title":"Ann Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.breast.2026.104894_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1634\/theoncologist.6-suppl_3-30","article-title":"Theoretical concepts and the emerging role of taxanes in adjuvant therapy","volume":"6","author":"Norton","year":"2001","journal-title":"Oncologist"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:28:38Z","timestamp":1789612118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626002043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":29,"alternative-id":["S0960977626002043"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104894","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104894"}}